直接口服抗凝药用于合并甲状腺功能亢进的房颤患者
在台湾全国性回顾性队列中,合并甲亢的非瓣膜性房颤患者使用DOAC(3213例)与华法林(1181例)相比,主要出血风险更低(HR 0.65),缺血性卒中/系统性栓塞风险相当。无甲亢患者中两药风险相当;服华法林者中甲亢患者缺血性卒中/系统性栓塞风险低于无甲亢者(HR 0.61)。作者认为DOAC可能为有效且更安全的替代选择,需进一步前瞻性研究验证。
要点
- 合并甲亢的NVAF患者中,DOAC较华法林主要出血风险更低(HR 0.65,95%CI 0.44-0.96,P=0.0295)。
- 合并甲亢的NVAF患者中,DOAC与华法林缺血性卒中/系统性栓塞风险相当。
- 服华法林者中,合并甲亢患者缺血性卒中/系统性栓塞风险低于无甲亢者(HR 0.61,95%CI 0.43-0.86,P=0.0050)。
核心结论
- 在合并甲亢的亚洲NVAF患者中,DOAC可能为有效且更安全的华法林替代选择。
- 作者认为此类患者可考虑使用DOAC进行血栓预防,并强调需进一步前瞻性研究验证。
研究设计与样本
- 全国性回顾性队列研究,使用台湾全民健康保险研究资料库数据。
- 纳入2012年6月1日至2017年12月31日合并甲亢的NVAF患者:服DOAC 3213例、服华法林1181例。
- 同时纳入无甲亢的NVAF患者:服DOAC 53591例、服华法林16564例。
- 采用倾向评分稳定权重(PSSW)平衡各组协变量。
- 另按1:4匹配服DOAC者(合并甲亢3213例 vs 无甲亢12852例)及服华法林者(合并甲亢1181例 vs 无甲亢4724例)。
主要发现
- 经PSSW后,合并甲亢患者中DOAC较华法林主要出血风险更低(HR 0.65;95%CI 0.44-0.96;P=0.0295)。
- 经PSSW后,合并甲亢患者中DOAC与华法林缺血性卒中/系统性栓塞风险相当。
- 合并甲亢与无甲亢患者之间,缺血性卒中/系统性栓塞及主要出血风险均相当。
- 服华法林者中,合并甲亢患者较无甲亢患者缺血性卒中/系统性栓塞风险更低(HR 0.61;95%CI 0.43-0.86;P=0.0050)。
临床怎么用
- 作者认为,合并甲亢的NVAF患者可考虑使用DOAC进行血栓预防。
- 作者认为DOAC可能为合并甲亢的NVAF患者有效且更安全的华法林替代选择。
- 作者强调需进一步前瞻性研究验证该发现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with hyperthyroidism were excluded from the randomized clinical trials of direct oral anticoagulants (DOACs) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). METHODS: We performed a nationwide retrospective cohort study using data from the Taiwan National Health Insurance Research Database. We enrolled 3213 and 1181 NVAF patients with hyperthyroidism who were taking DOACs and warfarin, respectively, from June 1, 2012 to December 31, 2017. We also enrolled 53 591 and 16 564 NVAF patients without hyperthyroidism, taking DOACs and warfarin, respectively. We used propensity score stabilized weights (PSSWs) to balance covariates across the study groups. We also used 1:4 matching on both taking DOACs, with (n = 3213) and without hyperthyroidism (n = 12 852); and both taking warfarin, with (n = 1181) and without hyperthyroidism (n = 4724). RESULTS: After PSSW, DOAC had a comparable risk of ischemic stroke/systemic embolism (IS/SE) and a lower risk of major bleeding (hazard ratio [HR] 0.65; 95% confidential interval [CI], 0.44-0.96; P = 0.0295) than warfarin among patients with hyperthyroidism. There were comparable risks of IS/SE and major bleeding between those patients with and without hyperthyroidism. However, among patients taking warfarin, those with hyperthyroidism had a lower risk of IS/SE than those without hyperthyroidism (HR 0.61; 95% CI, 0.43-0.86; P = 0.0050). CONCLUSION: Among NVAF Asian patients with concomitant hyperthyroidism, DOACs may be an effective and safer alternative to warfarin. Thromboprophylaxis with DOACs may be considered for such patients, and it is important to validate this finding in further prospective study.
引用
- Chan YH, Wu LS, See LC, et al. Direct Oral Anticoagulants in Atrial Fibrillation Patients With Concomitant Hyperthyroidism. J Clin Endocrinol Metab. 2020. PMID: 32009154. doi:10.1210/clinem/dgaa050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。